GEP201706651B - Rapamycin composition - Google Patents
Rapamycin compositionInfo
- Publication number
- GEP201706651B GEP201706651B GEAP201213520A GEAP2012013520A GEP201706651B GE P201706651 B GEP201706651 B GE P201706651B GE AP201213520 A GEAP201213520 A GE AP201213520A GE AP2012013520 A GEAP2012013520 A GE AP2012013520A GE P201706651 B GEP201706651 B GE P201706651B
- Authority
- GE
- Georgia
- Prior art keywords
- poly
- rapamycin composition
- ethylene oxide
- rapamycin
- oxide
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- -1 poly(ethylene oxide) Polymers 0.000 abstract 2
- 229920008712 Copo Polymers 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/324,407 US8912215B2 (en) | 2011-12-13 | 2011-12-13 | Rapamycin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP201706651B true GEP201706651B (en) | 2017-04-10 |
Family
ID=48572556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201213520A GEP201706651B (en) | 2011-12-13 | 2012-12-13 | Rapamycin composition |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8912215B2 (enExample) |
| EP (1) | EP2790700B1 (enExample) |
| JP (1) | JP6077001B2 (enExample) |
| CN (1) | CN104379215B (enExample) |
| GE (1) | GEP201706651B (enExample) |
| RU (1) | RU2557919C1 (enExample) |
| UA (1) | UA115137C2 (enExample) |
| WO (1) | WO2013090602A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| CN105794803B (zh) * | 2016-05-06 | 2018-06-05 | 重庆大学 | Tor蛋白抑制剂抑制植物枯萎病菌、黄萎病菌的新用途 |
| CN105918330B (zh) * | 2016-05-24 | 2018-06-05 | 重庆大学 | 雷帕霉素抑制植物早疫病菌的新用途 |
| CN112137961A (zh) * | 2020-09-30 | 2020-12-29 | 严鹏科 | 一种雷帕霉素组合物及其制备方法 |
| WO2023145867A1 (ja) * | 2022-01-31 | 2023-08-03 | 住友精化株式会社 | 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
| US6277410B1 (en) * | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
| US5840319A (en) | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
| US7205279B2 (en) * | 1995-10-25 | 2007-04-17 | Novartis Ag | Pharmaceutical compositions |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
| CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US8257725B2 (en) | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| ES2428354T3 (es) | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
| US9216106B2 (en) | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| CN101137365A (zh) | 2005-03-08 | 2008-03-05 | 生命周期药物公司 | 包含西罗莫司和/或其类似物的药物组合物 |
| JP2008533204A (ja) | 2005-03-21 | 2008-08-21 | マクサイト, インコーポレイテッド | 病気又は症状の治療のためのドラッグ送達システム |
| US20060247265A1 (en) | 2005-04-28 | 2006-11-02 | Clackson Timothy P | Therapies for treating disorders of the eye |
| US20090053391A1 (en) | 2005-12-06 | 2009-02-26 | Ludwig Florian N | Method Of Coating A Drug-Releasing Layer Onto A Substrate |
| BRPI0707612B8 (pt) | 2006-02-09 | 2021-05-25 | Macusight Inc | vaso lacrado e formulações líquidas contidas no mesmo |
| US8148338B2 (en) * | 2006-02-22 | 2012-04-03 | Supratek Pharma Inc. | Doxorubicin formulations for anti-cancer use |
| EP2001466B1 (en) | 2006-03-23 | 2016-01-06 | Santen Pharmaceutical Co., Ltd | Low-dose rapamycin for the treatment of vascular permeability-related diseases |
| WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| GB0625844D0 (en) | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| WO2009005673A1 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
| US20090035381A1 (en) | 2007-08-01 | 2009-02-05 | Stankus John J | Electrospraying method for fabrication of particles and coatings and treatment methods thereof |
| WO2009023877A2 (en) | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| CA2696977C (en) | 2007-10-16 | 2012-12-04 | Pharmathen S.A. | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof |
| EP2227085A4 (en) | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
| US20090291073A1 (en) | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| US20100040669A1 (en) | 2008-08-12 | 2010-02-18 | Higuchi John W | Non-Invasive Ocular Delivery of Rapamycin |
| EP2427174A4 (en) | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
| CA2665956A1 (en) | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| WO2011135580A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of sirolimus |
-
2011
- 2011-12-13 US US13/324,407 patent/US8912215B2/en not_active Expired - Fee Related
-
2012
- 2012-12-13 UA UAA201407624A patent/UA115137C2/uk unknown
- 2012-12-13 RU RU2013145610/15A patent/RU2557919C1/ru active
- 2012-12-13 EP EP12858609.6A patent/EP2790700B1/en not_active Not-in-force
- 2012-12-13 JP JP2014547437A patent/JP6077001B2/ja not_active Expired - Fee Related
- 2012-12-13 WO PCT/US2012/069544 patent/WO2013090602A2/en not_active Ceased
- 2012-12-13 GE GEAP201213520A patent/GEP201706651B/en unknown
- 2012-12-13 CN CN201280061480.1A patent/CN104379215B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013090602A3 (en) | 2014-12-24 |
| UA115137C2 (uk) | 2017-09-25 |
| JP2015513311A (ja) | 2015-05-07 |
| EP2790700B1 (en) | 2017-10-25 |
| WO2013090602A2 (en) | 2013-06-20 |
| US8912215B2 (en) | 2014-12-16 |
| RU2557919C1 (ru) | 2015-07-27 |
| EP2790700A4 (en) | 2015-10-14 |
| CN104379215A (zh) | 2015-02-25 |
| CN104379215B (zh) | 2017-08-04 |
| EP2790700A2 (en) | 2014-10-22 |
| JP6077001B2 (ja) | 2017-02-08 |
| US20130150397A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013012476A3 (en) | Branched polyether-polyamide block copolymers and methods of making and using the same | |
| IL268295B (en) | Parasitic preparations containing the active ingredient isoxazoline, methods and uses thereof | |
| WO2013119916A3 (en) | Compounds for treating spinal muscular atrophy | |
| PH12012501355A1 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
| WO2014052836A3 (en) | Methods and compositions for treating infection | |
| HK1202313A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| MX2014008008A (es) | Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. | |
| EP2578033A4 (en) | Hybrid mobile phone geopositioning | |
| WO2012167171A3 (en) | Z-selective ring-closing metathesis reactions | |
| EP2389894A3 (en) | Hydrogel implants with varying degrees of crosslinking | |
| GEP201706651B (en) | Rapamycin composition | |
| EP2558431A4 (en) | Narrow psd hydraulic cement-scm blends, and methods for making same | |
| IN2014DN06202A (enExample) | ||
| GB2496828B (en) | TTI Adaptation in E-DCH | |
| WO2012142292A3 (en) | Biofunctionalized polymer microparticles for biotherapeutic delivery and processes for using and making the same | |
| WO2012106702A3 (en) | Treatment of leukemia | |
| BR112012000506A2 (pt) | composições de copolímero em bloco de óxido de etileno óxido de butileno | |
| SG10201710919QA (en) | Bleed resistant, oil-extended olefin block copolymer composition with surface-active agent | |
| WO2013013240A3 (en) | Macrocyclic compounds and related compositons and methods of use | |
| 苏柚 | Special Talk Of AN JELL | |
| 肖昕 | Luxgen7 SUV | |
| 周静 | Purple Onion | |
| 朱慧 | Twenty-One Forever | |
| 罗晓立 | The Wizarding World of Harry Potter | |
| 王俐 | Forgiveness |